Amerikanische Gesellschaft für Hirudotherapie

Peripheral Artery Disease (Claudication, Investigational)

Highly investigational adjunct for intermittent claudication; ABI must be assessed first; critical limb ischemia is an absolute contraindication.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for peripheral artery disease. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for PAD is highly investigational.
Welche Evidenz existiert?
Tier C (highly investigational). A handful of small uncontrolled case reports describe walking-distance improvement; there are no randomized controlled trials and no data on amputation, MI, or stroke prevention. Evidence-based PAD care per AHA/ACC 2016 guidelines includes smoking cessation, statin therapy, antiplatelet medication (aspirin or clopidogrel), structured supervised exercise (the strongest evidence for claudication), and revascularization (angioplasty / bypass) for lifestyle-limiting disease or critical limb ischemia. Leech therapy on a leg with poor arterial flow can cause tissue breakdown.
Hauptrisiken
  • Tissue breakdown, non-healing wound, or gangrene if applied to a limb with low ABI (under 0.6) — this is the dominant risk
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Local skin infection or, rarely, Aeromonas infection
  • Worsening anemia from cumulative blood loss
  • Allergic reaction to leech saliva (uncommon)
  • Bleeding interaction with antiplatelet medications (aspirin, clopidogrel) — usually required for PAD
  • Delay or replacement of evidence-based therapy with risk of amputation, MI, or stroke
Wer dies nicht in Betracht ziehen sollte
  • Patients with ABI under 0.6 (critical limb ischemia)
  • Patients on antiplatelet therapy (aspirin, clopidogrel) — required for most PAD patients
  • Patients with a diabetic foot ulcer or active gangrene
  • Patients within 6 weeks of vascular intervention (angioplasty, stenting, bypass)
  • Patients with rest pain or non-healing wounds (urgent vascular surgery indication)
  • Patients with active infection, hemophilia, or severe anemia
Was Sie Ihren Kliniker fragen sollten
  • What is my ankle-brachial index (ABI) and toe-brachial index, and what is my Rutherford / Fontaine class?
  • Am I on a statin and appropriate antiplatelet therapy?
  • Have I tried supervised exercise therapy — the highest-evidence intervention for claudication?
  • Am I a candidate for revascularization (angioplasty, stent, bypass)?
  • What is my vascular surgery team's opinion on adjunctive complementary therapy?
  • If antiplatelet must continue, is leech therapy compatible at all?
  • What is the practitioner's experience and Aeromonas-prevention plan?
Wann dringende medizinische Versorgung suchen
  • Sudden severe leg pain, coldness, pallor, or pulselessness (acute limb ischemia — call 911)
  • Rest pain that interferes with sleep, or a non-healing leg or foot wound
  • New gangrene, blackening, or ulceration
  • Chest pain, pressure, or shortness of breath
  • Sudden weakness, slurred speech, facial droop, or vision loss
  • Bleeding from a bite site lasting more than 24 to 48 hours, fever, spreading redness, or pus
  • Hives, throat tightness, or breathing difficulty

Was dies NICHT bedeutet

  • This is not FDA-cleared for peripheral artery disease.
  • Small uncontrolled reports do NOT establish efficacy on walking distance vs. supervised exercise or on cardiovascular outcomes.
  • Mechanism rationale (microvascular flow) does NOT fix proximal arterial stenosis.
  • Leech therapy is NEVER a substitute for supervised exercise, statin / antiplatelet therapy, or revascularization when indicated.
  • Critical limb ischemia requires urgent vascular surgical evaluation, NOT complementary therapy.

Clinical Profile

Category
cardiovascular
ICD-10
I70.211, I70.212, I70.213, I73.9
Safety tier
high

Evidence Summary

Peripheral artery disease management follows AHA/ACC guidelines: smoking cessation, statin and antiplatelet therapy, supervised exercise, and revascularization for lifestyle-limiting claudication or critical limb ischemia. No controlled trial or case series of hirudotherapy for PAD or claudication has been published; use for this indication is investigational and mechanistic only. Critical safety: leech application to a limb with an ankle-brachial index <0.6 risks tissue breakdown and gangrene, and most PAD patients require antiplatelet therapy, which is an exclusion for leech application.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Andereya S et al. (2008), n=18

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Active deep vein thrombosis (acute phase <2 weeks)
  • Critical limb ischemia (ABI <0.4)
  • ABI <0.6 (critical limb ischemia)
  • Antiplatelet therapy (aspirin, clopidogrel) — absolute exclusion
  • Diabetic foot ulcer or active gangrene
  • Recent vascular intervention (<6 weeks)
  • Concurrent statin-related rhabdomyolysis

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Peripheral Artery Disease (Claudication, Investigational) — Hirudotherapy Evidence | ASH